Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics and safety of recombinant luteinising hormone in men with acquired hypogonadotropic hypogonadism
2019-004677-12Phase 2Active
- Sponsor
- Università degli Studi di Modena e Reggio Emilia
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutropin alfa and human chorionic gonadotropin in acquired hypogonadotropic hypogonadism (AHH) (2 arms), sponsored by Università degli Studi di Modena e Reggio Emilia. Primary endpoints: Total testosterone serum level increase and Dose-response curve of testosterone increase during LH administration. Started Oct 2020; status: active.
02
Drugs
lutropin alfahuman chorionic gonadotropin
03
Conditions
acquired hypogonadotropic hypogonadism (AHH)
Beyond the preview
Go deeper on 2019-004677-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004677-12.